Research: JOHNSON and COLLEAGUES,

Listed in Issue 176

Abstract

JOHNSON and COLLEAGUES,  Department of Child and Adolescent Psychiatry, Goteborg University, Goteborg, Sweden. mats.k.johnson@vgregion.se studied the role of omega-3 and -6 fatty acids in attention deficit hyperactivity disorder (ADHD).

Background

The aim of the study was to assess omega 3/6 fatty acids (eye q) in attention deficit hyperactivity disorder (ADHD).

Methodology

The study included a randomized, 3-month, omega 3/6 placebo-controlled, one-way crossover trial with 75 children and adolescents (8-18 years), followed by 3 months with omega 3/6 for all. Investigator-rated ADHD Rating Scale-IV and Clinical Global Impression (CGI) scale were outcome measures.

Results

A majority did not respond to omega 3/6 treatment. However, a subgroup of 26% responded with more than 25% reduction of ADHD symptoms and a drop of CGI scores to the near-normal range. After 6 months, 47% of all showed such improvement. Responders tended to have ADHD inattentive subtype and comorbid neurodevelopmental disorders.

Conclusion

A subgroup of children and adolescents with ADHD, characterized by inattention and associated neurodevelopmental disorders, treated with omega 3/6 fatty acids for 6 months responded with meaningful reduction of ADHD symptoms.

References

Johnson M, Ostlund S, Fransson G, Kadesjo B and Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. Journal of Attention Disorders. 12(5): 394-401. Mar 2009.

Munro Hall Clinic 2019

IJCA 2018 New Skyscraper

Scientific and Medical Network 2

Cycle India 2020

Walk on the Wide Side Trek Kenya 2020

Big Heart Bike Ride South Africa 2020

Scientific and Medical Network 2021

top of the page